NeuroKaire, a Kearny, NJ-based biotechnology company specializing in precision medicine in psychiatry and neurology, raised $10M in funding.
The round was led by GreyBird Ventures, with participation from Meron Capital, Jumpspeed Ventures.
The company intends to use the funds to scale operations and further expand pharmaceutical partnerships.
Led by CEO and Founder Talia Cohen Solal, NeuroKaire is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases. Its proprietary and innovative technology helps physicians find the best treatment for their patients. The company uses its neuronal readout technology to rapidly test approved antidepressants and drug combinations against an individual patient’s unique neurological biomarkers. Combined with patients’ genetic and medical history, NeuroKaire can improve selection of the optimal drug therapy for each patient.
NeuroKaire also enables pharmaceutical and biotechnology companies to bring precision medicine into drug development throughout the developmental pipeline across psychiatry and neurology.
Based on a simple blood draw, the company can provide a new view into brain function, including drug response insights that are based on the combined neurobiology and clinical context of individual patients. This test can help clinicians identify the optimal antidepressant based on the unique response of the patient’s brain cells. The test includes a readout of antidepressant effects from each patient’s derived neurons, clinical data, as well as a pharmacogenetic screening covering 132 drugs.
